<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00103558</url>
  </required_header>
  <id_info>
    <org_study_id>152-30</org_study_id>
    <nct_id>NCT00103558</nct_id>
  </id_info>
  <brief_title>Lumiliximab in Combination With FCR in Subjects With Relapsed Chronic Lymphocytic Leukemia (CLL)</brief_title>
  <official_title>A Phase I/II Study of Lumiliximab in Combination With Fludarabine, Cyclophosphamide, and Rituximab in Subjects With Relapsed Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biogen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biogen</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open label, Phase I/II, dose escalation research study of an investigational&#xD;
      product called lumiliximab, given with FDA (Food and Drug Administration) approved products&#xD;
      fludarabine, cyclophosphamide, and rituximab (FCR). The study duration is 17 visits over 42&#xD;
      months or until your disease progresses and you require additional CLL therapy. The total&#xD;
      duration of participation in the study will be approximately 4 years, however your disease&#xD;
      status will be followed indefinitely (forever).&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>March 2004</start_date>
  <completion_date type="Actual">March 2010</completion_date>
  <primary_completion_date type="Actual">January 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Characterize the safety profile</measure>
    <time_frame>monthly until month 12, then every 3 months for 24 months, then every 6 months until month 48</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Evaluate the pharmacokinetics of lumiliximab and rituximab</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <enrollment type="Actual">31</enrollment>
  <condition>Chronic Lymphocytic Leukemia</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Lumiliximab with FCR</intervention_name>
    <description>Dose, schedule, and duration specified in protocol</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age: 18 years and older&#xD;
&#xD;
          -  Diagnosis of B-cell CLL by International Workshop on CLL (IWCLL) response criteria&#xD;
&#xD;
          -  Relapsed CD23+ B-cell CLL&#xD;
&#xD;
          -  Rai Stage III or IV, or Rai Stage I or II if determined to have disease progression as&#xD;
             evidenced by rapid doubling or peripheral lymphocyte count, progressive&#xD;
             lymphadenopathy, progressive splenomegaly, or B symptoms&#xD;
&#xD;
          -  Prestudy WHO Performance Status less than or equal to 2&#xD;
&#xD;
          -  Signed, written Institutional Review Board (IRB)-approved informed consent&#xD;
&#xD;
          -  Men &amp; women of reproductive potential must agree to follow accepted birth control&#xD;
             methods during treatment for 3 months after completion of treatment&#xD;
&#xD;
          -  Acceptable liver function: Bilirubin less than or equal to 2.0 mg/dL (26 Âµmol/L), AST&#xD;
             (SGOT) &amp;/or ALT (SGPT) less than or equal to 2 times upper limit of normal&#xD;
&#xD;
          -  Acceptable hematologic status: Platelet count less than or equal to 50 x 10^9/L, ANC&#xD;
             less than or equal to 1 x 109/L&#xD;
&#xD;
          -  Acceptable renal function: Serum creatinine less than or equal to 1.5 times upper&#xD;
             limit of normal&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Subjects who did not respond to prior FCR therapy (relapsed within 6 months of the&#xD;
             last dose).&#xD;
&#xD;
          -  Cancer radiotherapy, radioimmunotherapy, biological therapy, chemotherapy, or other&#xD;
             investigational therapy within 4 weeks prior to Study Day 1&#xD;
&#xD;
          -  Previous exposure to lumiliximab or other anti-CD23 antibodies&#xD;
&#xD;
          -  Subjects who have had a prior allogenic bone marrow transplant (BMT) or autologous BMT&#xD;
             or peripheral stem-cell transplant (PBSCT)&#xD;
&#xD;
          -  Known infection with HIV, hepatitis B, or hepatitis C&#xD;
&#xD;
          -  Uncontrolled diabetes mellitus&#xD;
&#xD;
          -  Uncontrolled hypertension&#xD;
&#xD;
          -  Transformation to aggressive B-cell malignancy (e.g., larger B-cell lymphoma,&#xD;
             Richter's Syndrome, or prolymphocyte leukemia (PLL)&#xD;
&#xD;
          -  Subjects with secondary malignancy requiring active treatment (except hormonal&#xD;
             therapy)&#xD;
&#xD;
          -  Subjects with medical conditions currently requiring long-term use (less than 1 month)&#xD;
             of systemic corticosteroids&#xD;
&#xD;
          -  Serious nonmalignant disease or laboratory abnormality, which, in the opinion of the&#xD;
             investigator &amp;/or sponsor, would compromise protocol objectives&#xD;
&#xD;
          -  Active uncontrolled bacteria, viral, or fungal infections&#xD;
&#xD;
          -  New York Heart Association Class III or IV cardiac disease, myocardial infarction&#xD;
             within the past 6 months prior to Study Day 1, unstable arrhythmia, or evidence of&#xD;
             ischemia on ECG within 14 days prior to Study Day 1&#xD;
&#xD;
          -  Seizure disorders requiring anticonvulsant therapy&#xD;
&#xD;
          -  Severe chronic obstructive pulmonary disease with hypoxemia&#xD;
&#xD;
          -  Major surgery, other than diagnostic surgery, within 4 weeks prior to Study Day 1&#xD;
&#xD;
          -  Clinically active autoimmune disease&#xD;
&#xD;
          -  Subjects with a history of fludarabine-induced autoimmune cytopenia&#xD;
&#xD;
          -  Pregnant or currently breast-feeding&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Medical Director</last_name>
    <role>Study Director</role>
    <affiliation>Biogen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Research Site</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <reference>
    <citation>Pathan NI, Chu P, Hariharan K, Cheney C, Molina A, Byrd J. Mediation of apoptosis by and antitumor activity of lumiliximab in chronic lymphocytic leukemia cells and CD23+ lymphoma cell lines. Blood. 2008 Feb 1;111(3):1594-602. Epub 2007 Nov 21.</citation>
    <PMID>18032710</PMID>
  </reference>
  <reference>
    <citation>Byrd JC, O'Brien S, Flinn IW, Kipps TJ, Weiss M, Rai K, Lin TS, Woodworth J, Wynne D, Reid J, Molina A, Leigh B, Harris S. Phase 1 study of lumiliximab with detailed pharmacokinetic and pharmacodynamic measurements in patients with relapsed or refractory chronic lymphocytic leukemia. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4448-55.</citation>
    <PMID>17671129</PMID>
  </reference>
  <verification_date>May 2010</verification_date>
  <study_first_submitted>February 10, 2005</study_first_submitted>
  <study_first_submitted_qc>February 10, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 11, 2005</study_first_posted>
  <disposition_first_submitted>September 17, 2015</disposition_first_submitted>
  <disposition_first_submitted_qc>September 17, 2015</disposition_first_submitted_qc>
  <disposition_first_posted type="Estimate">October 2, 2015</disposition_first_posted>
  <last_update_submitted>September 17, 2015</last_update_submitted>
  <last_update_submitted_qc>September 17, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">October 2, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted, but a results disposition has been submitted           -->
</clinical_study>

